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DREWNOWSKI, A., J. A. GRINKER, R. GRUEN AND A. C. SULLIVAN. Effects of inhibitors of carbohydrate 
absorption or lipid metabolism on meal patterns of Zucker rats. PHARMACOL BIOCHEM BEHAV 23(5) 811-821, 
1985.--Peripherally active anorectic agents represent a new approach to the pharmacological management of obesity. Two 
inhibitors of carbohydrate absorption: an alpha-glucosidase inhibitor, acarbose (Bay g 5421) and an alpha-amylase in- 
hibitor, Ro 12-2272, were compared with two novel inhibitors of lipid metabolism: an inhibitor of human pancreatic lipase 
(Ro 20-0083) and of hepatic fatty acid synthesis (Ro 22-0654). All drugs were presented as diet admixtures over 3 or 4 
consecutive days. Total food and water intakes, the temporal pattern of feeding, and the average meal frequency and meal 
size were measured using computerized data collection procedures. Inhibitors of carbohydrate absorption failed to sup- 
press food intake in either obese or lean Zucker rats and had no effect on the parameters of feeding. In contrast, inhibitors 
of lipid metabolism reduced food intake by 56-77% by reducing both meal frequency and meal size. Direct inhibition of lipid 
metabolism may be a viable mechanism for anti-obesity agents. 
Meal patterns Zucker rats 
Lipid metabolism inhibitors 
Antiobesity drugs Carbohydrate absorption inhibitors 
CURRENTLY employed anorectic agents such as mazindol 
or fenfluramine suppress appetite through direct action on 
the central nervous system [26]. Although these compounds 
may be useful as short-term adjuncts to weight reduction 
programs, their chronic use has been restricted due to unde- 
sirable CNS side effects, potential for addiction, and in par- 
ticular, the development of tolerance [26,28]. 
Anorectic agents acting through peripheral mechanisms 
represent a new approach to the pharmacological manage- 
ment of obesity. The primary effects of these compounds 
may include a delay in gastric emptying, changes in intestinal 
absorption, or interference with hepatic carbohydrate or 
lipid metabolism [7, 26, 28]. However, these compounds 
may also affect food intake [26-28, 30], and so alter the en- 
ergy balance of the organism. The peripheral mechanisms 
underlying the regulation of food intake are still unclear, but 
are thought to include hormonal and metabolic feedback 
signals operating between gastrointestinal and hepatic sites 
and the central nervous system [28]. 
Peripheral anorectic agents currently under investigation 
include compounds that inhibit the absorption of carbo- 
hydrates in the gastrointestinal tract. Among these are acar- 
bose (Bay g 5421, Bayer) and Ro 12-2272 (Hoffmann-La 
Roche). Both are complex oligosaccarides of microbial ori- 
gin. Acarbose is a potent alpha-glucosidase inhibitor and has 
shown activity against several carbohydrate digestive 
enzymes including alpha-amylase, sucrase and maltase 
[18,19]. It is reported to inhibit the breakdown of starches 
and sugar polymers containing alpha 1,4-glucose linkages by 
glucosidase enzymes located in the mucosa of the small in- 
testine, and to block the rise of serum glucose, insulin and 
triglycerides following a glucose-rich meal [18,19]. At suffi- 
ciently high doses it inhibits the absorption of carbohydrate 
completely [4]. Ro 12-2272 is an inhibitor of alpha-amylase 
similar in its structure and effects to the alpha-amylase in- 
hibitor Bay e 4609 (Bayer) [18]. The latter drug is also a 
complex oligosaccharide that is a specific and potent in- 
hibitor of alpha-amylase in vitro as well as in vivo. It reduces 
the increase in blood glucose and insulin levels in humans 
and rats following a starch load [18]. 
A second class of novel pharmacological agents directly 
inhibits lipid absorption or synthesis. These include Ro 22- 
0654 (4-amino-5-ethyl-3-thiophene carboxylic acid methyl 
ester HCI, Hoffmann-LaRoche), which is a novel and potent 
inhibitor of hepatic fatty acid synthesis [29] and Ro 20-0083 
(dinitrodescarboxylasalocid, Hoffmann-LaRoche), an in vitro 
inhibitor of human pancreatic lipase which also inhibits in vivo 
lipid absorption and synthesis in rats [6]. Body composition 
studies indicated that the weight loss in obese and lean 
Zucker rats following chronic treatment with Ro 22-0654 was 
attributable primarily to a significant decrease in carcass 
lipid content [29]. Oral administration of Ro 20-0083 in doses 
of 56, 120, and 240 mg/kg body weight produced significant 
and dose-dependent inhibition of lipid absorption and de 
novo fatty acid synthesis [6]. Chronic administration of Ro 
20-0083 to obese female Zucker rats at doses of 250 mg/kg 
body weight resulted in reduced body weight gain and lower 
carcass fat and triglyceride levels [6]. 
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TABLE 1 
EFFECTS OF ACARBOSE ON DAILY FOOD AND WATER INTAKES AND MEAL 
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18.33 3.93 17.20 2.82 
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Most of these peripheral anorectic agents have been re- 
ported to suppress body weight gain or to reduce body 
weight in rats following chronic treatment ranging from 4 to 
38 weeks. However, it is uncertain to what extent these ef- 
fects are mediated by a reduction in food intake. For exam- 
ple, some investigators have reported concordant decreases 
in food intake and body weight gain following chronic treat- 
ment with acarbose [17,18], while others reported an in- 
crease in food intake but a reduction in body weight [ 11). The 
two inhibitors of lipid metabofism under investigation, Ro 
22-06.54 and Ro 20-0083, are also reported to reduce body 
weight following chronic treatment [6,29]. However. their 
effects on food intake have not been investigated in detail. 
To understand the mode of action of peripheral anorectic 
agents, it is important to know how pharmacological activity 
is related to the diurnal shifts in energy metabolism or to the 
regulatory systems of appetite and satiety [8,13]. The tech- 
nique of meal pattern analysis allows the measurement of 
food intake in freely feeding rats over several days. Study of 
the parameters of feeding behavior can show how putative 
anorectic agents influence the circadian distribution of food 
intake, mean daily meal frequency and average meal size. 
This methodology has a clear advantage over procedures 
whereby drugs are administered after a period of food depri- 
vation and food intake is monitored for periods up to 24 
hours. The deprivation paradigm is known to heighten the 
anorectic effect of certain pha~acologicai agents such as 
d-amphetamine [2,13], and may obscure the drugs’ effects on 
the temporal patterns of food intake. Reduction in intake 
combined with rebound hyperphagia occurring within the 24 
hour period may lead to unchanged total intakes. The pres- 
ent methodology permits the determination of the size of 
individual meals both at night and during the day, and the 
assessment of the effects of drugs on the initiation and termi- 
nation of meals. 
In the present study, we examined the effects of two 
classes of compounds on food and water intakes of freely 
feeding rats and on the microstructure of feeding. In Exper- 
iment 1 we examined the effects of two inhibitors of carbo- 
hydrate absorption (acarbose and Ro 12-2272), and in Exper- 
iment 2 we examined the effects of two inhibitors of lipid 
metabolism (Ro 20-0083 and Ro 22-0654). Measures of water 
intake were included to control against possible contributing 
effects of taste aversion or drug-induced general malaise. 
Since the effectiveness of these agents in the management of 
human obesity is of principal interest, all compounds were 
tested in the genetically obese Zucker rat, considered a use- 





Six genetically obese (faifa) and six lean (Fai-) experi- 
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FIG. 1. Temporal effects of administration of acarbose (BAY g 5421) on food intakes of obese and 
lean Zucker rats relative to the baseline condition in Experiment 1. Eight consecutive 3-hr time periods 
are shown, with the 12 hour dark phase (beginning at 1790) indicated by a solid bar. The 
data represent mean food intakes (in grams) during each 3 hr period. SEM bars are also indicated. 
mentally naive male Zucker rats were obtained from the 
Hoffmann-La Roche breeding colony. At the start of the ex- 
periment the rats were 13 weeks old. Obese rats weighed a 
mean of 462 g (range 402 to 512 g) and lean rats weighed a 
mean of 317 g (range 307 to 326 g). 
Dic>t 
The rats were accustomed to a diet of powdered Purina 
rat chow for 10 days prior to the start of the experiment. 
Caloric density of the diet was 3.5 kcal/g, and its composition 
according to the manufacturer’s specifications was 54% 
carbohydrate, 23% protein, 4.5% fat, 6.0% fiber, and 2.5% 
minerals, as well as moisture and ash. The rats had free access 
to water at all times. 
The rats were individually housed in Piexigias cages with 
stainless steel rod floors. The cages were placed in noise-, 
attenuating chambers under a computer-controlled light-dark 
cycie (lights on 5 a.m. to 5 p.m.) at a constant temperature of 
22°C. The rats had been accustomed to the apparatus for one 
week prior to the experiment. Details of the food-dispensing 
apparatus have been provided previously [251. 
DrldgS 
All drugs were provided as diet admixtures. Acarbose and 
Ro 12-2272 were provided in effective concentrations of 80 
mgilO0 g of diet. This dose corresponds to the highest dose 
of acarbose (80 mg/lOO g), also used as diet admixture in 
previous studies with female obese Zucker rats [ 181. Since 
the average food intake during the baseline period was 29.1 g 
for obese and 19.4 g for lean rats, the effective doses of acar- 
bose were 5.0 mg/lOO g body weight for the obese and 4.9 
mglfO0 g body weight for lean rats. The corresponding doses 
of Ro 12-2272 were 5.3 mg/lOO g body weight for the obese 
and 4.9 mg/lOO g body weight for lean rats. 
Experiment 1 began with a 4 day baseline period during 
which the rats ate the standard chow diet, followed by 4 
consecutive days of acarbose administration. At the end of 
acarbose treatment, the rats were again provided with the 
standard chow diet during 4 days of recovery. The rats were 
then given a rest period of one week to recover fully from 
any residual effects of acarbose. During the second phase of 
the experiment, the rats were monitored during a 4-day 
baseline period and during 4 days of Ro 12-2272 administra- 
tion. Meal patterns were not monitored during the recovery 
period following Ro 12-2272 administration. 
The apparatus used to monitor food intakes consisted of 
solid-food eatometers connected to an on-line PDP-8 com- 
puter [25]. Total food intake (minus spillage) was measured 
daily, and water intake was read from 100 ml graduated cyl- 
inders. 
All animals were serviced daily between 3:30 p.m. and 5 
p.m., immediately preceding the onset of the dark cycle. 
Food intakes, water intakes and body weights were recorded 
at that time, and food cups were cleaned, filled with fresh 
food or with the drug admixture and re-weighed. The rats’ 
feeding responses were continuously monitored by means of 
programs written to record all licks (or bites) of food be- 
tween 5 p.m. (the start of the dark period) and service time 
on the foilowing day. Daily records for up to 12 rats (6 obese 
and 6 lean) were obtained at one time. The servicing and data 
collection procedures have been described previously [25]. 
The computer-based collection criteria were set as low as 
possible to avoid eliminating potentially valuable data prior 
to inspection. For data collection purposes only, a minimum 
of one bite of food occurring within two seconds constituted 
the threshold criterion for the initiation of a recorded bout of 
feeding. A feeding bout was considered as terminated when 
no bites had been recorded for at least one minute. Analyses 
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of the temporal course of intake and of the principal param- 
eters of meal-taking behavior were carried out subsequently. 
During data analyses, we excluded from consideration as 
noise all feeding responses below 0. I g, and we used 15 
minutes as the intermeal interval (IM1) criterion. Thus, 
periods longer than 15 minutes constituted true intermeal 
intervals, while periods below 15 minutes were regarded as 
within-meal pauses. For a fuller discussion of the suitability 
of 15 minutes IM1 see previous literature [8, 9, 13]. 
Data Analysis 
The data were analyzed using analyses of variance 
(BMDP) for repeated measures. Rat genotype (obese vs. 
lean) was the between-subjects variable, while condition 
(baseline, drug or recovery), light phase (light vs. dark) or 
time periods [8] were the within-subject variables. Analyses 
of variance for each drug were conducted separately for the 
measures of food intake, meal frequency and meal size. Ad- 
ditional ANOVAS of condition by genotype were carried out 
for measures of 24 hour water intake. Significant ANOVA F 
values are presented for both main effects and for interac- 
tions. Differences between treatment means and baseline 
control were tested for significance using Dunnett 's  
t-statistic. When the main effects were not significant and in 
the absence of significant interactions, post hoc tests were 
not performed. 
RESULTS 
The effects of acarbose on food and water intakes are 
shown in Table 1. Analysis of data collected during the 
baseline period preceding drug administration showed that 
obese Zucker rats ate more food, ANOVA F(1,10)=62.67, 
p<0.01, than did lean rats. All rats ate more food at night 
than during the day. Obese Zucker rats also ate larger meals 
than did lean rats, F(1,10)=15.90, p<0.01, but both sets of 
rats ate the same number of meals per day [8,13]. 
Acarbose had no significant effects on the daily food in- 
takes of either lean or obese rats, F(2,20)= 1.75. Meal size, 
meal frequency, and the circadian distribution of food intake 
were unchanged by drug treatment and the temporal profile 
of intake (see Fig. 1) remained unaffected. Analysis of water 
intakes showed only that obese rats drank more water than 
the lean rats, F(1,30)=42.5, p<0.01, and no effects of the 
drug were observed. 
The effects of Ro 12-2272 on food and water intakes and 
meal parameters are summarized in Table 2. During the 
baseline period obese rats ate more food, F(1,10)=52.16, 
p<0.01,  and drank more water, F(1,20)=29.2, p<0.01, than 
did lean rats. All rats ate more food at night than during the 
day, F(1,10)=209.97, p<0.01. Ro 12-2272 had no significant 
effect on the daily food or water intakes, meal size, or meal 
frequency of obese or lean rats. As shown in Fig. 2, the drug 
had no effect on the temporal profile of intake. 
EXPERIMENT 2 
Among the most effective obesity promoting diets are 
those that are high in fat content [9, 15, 23]. Diets containing 
55% Crisco oil or lard, or "supermarket" diets consisting of 
sweetened condensed milk, cheese and cookies promote 
body weight gain and the proliferation of adipose tissue. Ge- 
netically obese Zucker rats in a 9-day self-selection study [5] 
as well as obese ob/ob mice [21] have been reported to over- 
eat fat at the expense of other nutrients, although the amount 
TABLE 2 
EFFECTS OF RO 12-2272 ON DAILY FOOD AND WATER INTAKES 
AND MEAL PARAMETERS (15 MIN IMI) OF OBESE AND LEAN 
ZUCKER RATS (MEAN _+ S.E.M.) 
Condition 
Baseline Drug 
Dark Light Dark Light 
Food intake (g) 
lean 
obese 






Water intake (ml) 
lean 
obese 
16.24 3.26 17.89 3.71 
-+0.76 -+0.40 +0.43 -+0.52 
26. I I 4.65 27.27 4.43 
-+1.58 +1.35 -+1.58 +1.21 
2.21 1.74 2.16 1.38 
+0.30 _+0.65 -+0.20 +0.23 
2.80 2.04 3.84 2.36 
-+0.23 -+0.70 -+0.62 -+0.54 
8.08 2.53 8.65 2.13 
___0.76 -+0.61 +0.65 -+0.22 
9.69 1.64 7.65 1.21 





of fat consumed may depend on the palatability of the other 
dietary selections available [10]. 
Inhibition of lipid synthesis and/or lipid absorption might 
therefore be expected to provide a direct pharmacological 
approach to the management of obesity. In previous studies 
[28] several inhibitors of lipid synthesis have demonstrated 
antiobesity activity in rodents. These agents include ( - ) -  
hydroxycitrate, an inhibitor of citrate cleavage enzyme; de- 
hydroepiandrosterone, an inhibitor of glucose-6-phosphate 
dehydrogenase, and nafenopin, an inhibitor of acetyl CoA 
carboxylase [28]. In the next portion of this study we exam- 
ined the effects of a novel inhibitor of hepatic fatty acid 
synthesis, Ro 22-0654, and an inhibitor of human pancreatic 
lipase, Ro 20-0083. 
METHOD 
Animals 
Five mature obese and five lean male Zucker rats from 
Experiment 1 were used. At the start of Experiment 2 the 
rats were 8 months old. Obese rats weighed a mean of 756 g 
(range 720 to 821 g) and lean rats weighed a mean of 490 g 
(range 428 to 524 g). 
Diet 
For three months prior to the start of and during Experi- 
ment 2 the rats were fed a semisynthetic diet (Bio-Serv). 
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FIG. 2. Temporal effects of administration of Ro 12-2272 (alpha-amylase inhibitor) on food intakes 
of obese and lean Zucker rats relative to the baseline condition in Experiment 1. Eight consecutive 3-hr 
time periods are shown, with the 12 hour dark phase (beginning at 17:00) indicated by a solid 




8 '  
$ 
3 
T A B L E  3 
EFFECTS OF RO 22-0654 ON DAILY FOOD AND WATER INTAKES AND MEAL 
PARAMETERS (15 MIN IMI) OF OBESE AND LEAN ZUCKER RATS (MEAN _+ S.E.M.) 
Condition 
Baseline Drug Recovery 
Dark Light Dark Light Dark Light 
Food intake (g) 
lean 
obese 






Water intake (ml) 
lean 
obese 
13.03 4.57 2.08* 1.96" 13.31 10.41" 
-+0.56 -+0.66 -+0.37 -+0.71 -+ 1.06 + 1.34 
13.12 11.05 5.43* 4.67* 12.05 13.56" 
-+1.13 -+1.12 -+0.65 -+0.79 -+0.96 -+1.14 
2.12 1.27 0.77* 0.93 3.20* 3.79* 
_+0.29 -+0.17 -+0.13 -+0.24 -+0.39 -+0.75 
2.32 2.13 1.67t 1.60 3.44* 3.49* 
-+0.19 -+0.25 -+0.39 -+0.23 -+0.55 -+0.48 
6,70 3.55 2.67* 1.62* 4.30* 3.20 
-+0.86 -+0.49 -+0.33 _ + 0 . 4 0  -+0.54 -+0.58 
5,72 5.38 3.63* 2.67* 4.30* 4.30 
-+0.49 -+0.58 -+0.53 -+0.53 -+0.85 -+0.62 
24.9 26.9 27.5 
-+1.5 -+1.9 +3.0 
27.7 23.3 26.3 
-+5.3 -+9.2 -+5.0 
*Dunnett 's  t-statistic: p<0.05 (two-tailed). 
tDunnet t ' s  t-statistic: p<0.05 (one-tailed). 
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FIG. 3. Temporal effects of administration of Ro 22-0654 (inhibitor of hepatic fatty acid synthesis) on 
food intakes of obese and lean Zucker rats in Experiment 2. Eight consecutive 3-hr time periods are 
shown, with the 12 hour dark phase (beginning at 17:00) indicated by a solid bar. The data represent 
mean food intakes (in grams) during each 3 hour period. SEM bars are also indicated. 
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FIG. 4. Effects of Ro 22-0654 on the 24 hour distribution of meal sizes of obese and lean Zucker rats 
in Experiment 2. The data represent the percentage contribution of different size meals to the total 
daily food intake. Meal sizes are calculated on the basis of 15 minutes 1MI criterion. 
Caloric density  o f  this diet was  4.1 kcal/g and its nutrient 
compos i t ion  was  60% glucose ,  l ~ c  corn oil, 23% vitamin- 
free casein,  5% Phillips and Hart modif ied  salt mix  IV, and 
1% vitamin mix.  
Drugs 
Both compounds  were  administered as diet admixtures.  
Ro 22-0654 was  given at a dose o f  322 mg/100 g diet and Ro 
20-0083 at a dose  of  774 mg/100 g diet. For an obese  Zucker 
rat weighing  750 g and consuming  25 g of  diet a day,  these  
concentrations are equivalent  to daily doses  o f  100 mg/kg 
body weight  for Ro 22-0654 and 240 mg/kg body weight for 
Ro 20-0083. The doses  selected were comparable  to the dose 
o f  80 mg/kg of  Ro 22-0654, reported to suppress  fatty acid 
synthes is  in vivo [29], and to the chronic orally administered 
dose  o f  250 mg/kg of  Ro 20-0083, reported to suppress  body 
weight  gain in obese  female  Zucker rats [6]. 
Procedures 
A four-clay baseline was  fo l lowed by three days of  Ro 
22-0654 treatment, and four days o f  recovery.  Because  of  
apparatus malfunct ion,  meal  pattern data for two of  the 
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TABLE 4 
EFFECTS OF RO 20-0083 ON F O O D  AND WATER INTAKES AND MEAL PARAMETERS 
(15 MIN IMI) OF OBESE AND L E A N  Z U C K E R  RATS (MEAN -+ S.E.M.) 
Condition 
Baseline Drug Recovery 
Dark Light Dark Light Dark Light 
Food intake (g) 
lean 
obese 
15.38 4.74 3.97* 1.67 18.57 6.41 
_+2.79 +1.36 _+0.52 _+0.37 _+2.05 _+1.63 
13.45 10.14 6.95* 3.46* 17.19 8.47 
_+ 1.54 _+ 1.09 + 1.93 +0.82 _+2.49 _+2.09 
Meal size (g) 
lean 
obese 
2.75 1.60 0.98* 0.92 4.11+ 2.28 
_+0.84 _+0.40 _+0.21 +0.16 -+0.62 --0.61 
2.59 2.70 1.41 1.47 3.61 2.62 




6.50 3.53 4.40* 1.87" 5.00* 3.10 
_+0.77 _+ 1.20 _+0.66 + -0 .39  -+0.35 -+0.73 
5.33 4.20 4.73 2.20* 4.90 3.205 
_+0.49 _+0.64 _+0.62 +0.34 -+0 .46  _+0.64 
Water intake (ml) 
lean 
obese 
28.5 30.7 26.5 
_+3.4 _+2.0 _+1.7 
31.7 24.1 33.3 
_+5.2 _+11.5 _+5.4 
*Dunnett's t-statistic: p<0.05 (two-tailed). 
+Dunnett's t-statistic: p<0.05 (one-tailed). 
animals were collected for only one day of recovery. All rats 
were then given a rest period of one week before the admin- 
istration of Ro 20-0083. In this phase of the experiment, the 
rats were monitored for three baseline days, that were fol- 
lowed by three days of drug administration and two days of 
recovery. 
RESULTS 
The effects of Ro 22-0654 on food and water intakes are 
summarized in Table 3. Analysis of food intake data col- 
lected during the baseline period showed that obese rats ate 
more food than did the lean rats, A N O V A  F(1,8)=17.84, 
p<0.01, and that both sets of rats ate more food at night than 
during the day, F(I,8)= 10.08, p<0.05. The circadian distri- 
bution of intake for obese rats was much less pronounced 
than had been observed for the same rats in Experiment 1. 
This result raises the possibility that the circadian pattern of 
intake distribution of obese (though not lean) Zucker rats 
changes with age [8]. 
Ro 22-0654 reduced the daily food intake of both obese 
and lean rats. The main effect of drug treatment was signifi- 
cant, F(2,16)= 121.48, p<0.01. The 24-hr food intakes of lean 
rats were reduced by 77% and those of obese rats by 58%. 
Food intake was reduced more at night than during the day 
as shown by the condition by time interaction, 
F(2,16)= 11.14, p<0.01. The genotype by condition by time 
interaction was also significant, F(2,16)=4.99, p<0.01, con- 
firming that the food intake of lean rats during the night was 
affected the most (84% reduction). During the recovery 
period, lean rats showed compensatory hyperphagia; food 
intakes during the light phase were significantly higher than 
light intakes during the baseline period, t(8)=3.91, p<0.05. 
The temporal profile of food intake during Ro 22-0654 
treatment is summarized in Fig. 3. Food intake of both obese 
and lean rats declined over the 24-hour period, and no rebound 
feeding was observed at any time. The condition by time in- 
teraction was significant, F( 14, i 12) = 1.93, p < 0.05. A s shown in 
Table 3, the reduction in food intake was associated with signif- 
icant reductions in meal size, F(2,16)=41.30, p<0.01, and in 
meal frequency, F(2,16)= 14.64, p<0.01. This was true for both 
genotypes and for both dark and light periods: both ANOVA 
main effects were significant and no significant interactions 
with genotype or time were observed. During the recovery 
period, meal size of lean and obese rats increased to above 
baseline values both at night and during the day. In contrast, no 
rebound was observed for meal frequency. The distribution of 
meal sizes during drug treatment days compared to baseline 
days is summarized in Fig. 4. Ro 22-0654 reduced the average 
meal sizes of both obese and lean rats by eliminating the largest 
meals. 
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FIG. 5. Temporal effects of administration of Ro 20-0083 (inhibitor of human pancreatic lipase) on 
food intakes of obese and lean Zucker rats in Experiment 2. Eight consecutive 3-hr time periods are 
shown, with the 12 hour dark phase (beginning at 17:00) indicated by a solid bar. The data represent 
mean food intakes (in grams) during each 3 hour period. SEM bars are also indicated. 
The effects of Ro 20-0083 on food and water intakes are 
summarized in Table 4. During the baseline period, the rats 
ate more food at night than during the day, F(1,8)=33.20, 
p<0.01, and obese rats ate more food than lean rats. Ro 
20-0083 reduced the food intake of lean rats by 72% and that 
of obese rats by 56%. The main effect of condition was signif- 
icant, F(2,16)=59.69, p<0.01. Food intake was reduced 
more at night than during the day, leading to a condition by 
time interaction, F(2,16)=3.68, p <0.05. Recovery following 
drug administration was complete within 3 days and no sig- 
nificant differences from baseline intake were observed. 
The temporal patterns of food intake are summarized in 
Fig. 5. Food intake of both obese and lean rats was reduced 
over the entire 24 hour period and no rebound feeding oc- 
curred. The condition by time interaction was again significant, 
F(14,112)=4.15, p<0.01. 
The observed decrease in food intake was achieved 
through significant reductions in meal size, F(2,16)= 18.60, 
p<0.01, and in meal frequency, F(2,16)=6.11, p<0.05. No 
main effects of genotype or time-related interactions were 
observed. The distribution of meal sizes during treatment 
days as compared to baseline days is summarized in Fig. 6. 
Ro 20-0083 reduced meal sizes of both obese and lean rats: 
meals consumed during the treatment period were primarily 
below 2 g for the obese and below 1 g for the lean rats. 
DISCUSSION 
Peripherally-acting antiobesity agents may influence en- 
ergy metabolism through modulation of nutrient absorption, 
endocrine function, or carbohydrate or lipid metabolism 
[26,28]. Some of the compounds have also been shown to 
affect overall food intake, presumably via an indirect mod- 
ulation of appetite and satiety mechanisms. Therefore, one 
important aspect of any pharmacological evaluation of these 
new agents is a detailed description of their action not only 
on the 24 hr food and water intakes but also on the diurnal 
patterns and parameters of feeding. 
Of the anorectic agents tested here, acarbose (Bay g 5421) 
is the most extensively studied. Previous research has 
primarily focused on the long term effects of acarbose on 
body weights of growing Sprague-Dawley or Zucker rats. In 
one study [17], the body weight gain of male and female 
obese Zucker rats (mean initial weights 324 and 293 g re- 
spectively) fed a semisynthetic diet containing 45% carbo- 
hydrate (starch and sucrose in equal amounts) was dose- 
dependently reduced over an 8 week period. The reduced 
body weight gain was reported to be due to a highly signifi- 
cant reduction of the total iipids in the carcass of obese rats 
[18]. In another experiment reported by these investigators 
[18], food intakes of mature obese male Zucker rats were 
reduced by 27% following administration of 40 mg/100 g diet 
for 28 days and by 34% following 80 rag/100 g diet. The rats" 
initial bodyweights were in the range 558-585 g and were 
reduced by as much as 100 g by the highest dose ofacarbose 
at the end of the test period. The same investigators have 
reported comparable results with female obese Zucker rats 
[18] after 34 weeks feeding of a sucrose containing diet to 
which 20, 40 or 80 mg acarbose per 100 g diet had been 
added. 
These data showing the effects of acarbose on obese 
Zucker rats are at variance with the results of a more recent 
study [30,31], in which growing 7 week old obese and lean 
Zucker rats were fed either 0, 20 or 40 mg of acarbose per 100 
g of diet (45% complex carbohydrate; 35% fat and 20% 
protein calories) for a period of 13 weeks. Obese Zucker rats 
showed no significant reductions in food intake. The per- 
centage of total body fat in the obese Zucker rats given acar- 
bose was not significantly reduced in spite of lowered final 
body weights. However, lean Zucker rats did show signifi- 
cant reductions in body weight and in cumulative food in- 
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FIG. 6. Effects of Ro 20-0083 on the 24 hour distribution of meal sizes of obese and lean Zucker rats 
in Experiment 2. The data represent the percentage contribution of different-size meals to the total 
daily food intake. Meal sizes are calculated on the basis of 15 minute IMI criterion. 
takes. At the highest dose of acarbose, the food intake of 
lean rats was reduced by 13% at the end of 13 weeks [30,31]. 
Further studies on the effects of acarbose were conducted 
on Sprague-Dawley rats also fed "obesogenic" diets con- 
taining sucrose. In one study [30,32], groups of six 12- 
week-old female Sprague-Dawley rats were fed a diet of 
powdered chow with access to a 40% sucrose solution. 
Acarbose was added per 100 g of chow in doses 0, 20 or 40 
mg for a period of 38 weeks. Analyses of the data showed no 
differences in daily caloric intakes, and thus no dose- 
dependent effect of acarbose on food intake between the 
three sucrose consuming groups. These authors failed to find 
any differences in cumulative caloric intakes of chow and 
sucrose or in cumulative total calories either between weeks 
1-20 or between weeks 21-38. However, in contrast to the 
stable food intake data, body weights of the 20 and 40 mg 
gro~ips were significantly below those of the 0 mg acarbose 
group by the conclusion of the experiment. Moreover, while 
the 0 mg group had become significantly obese as determined 
by percentage of carcass fat (30.3%), the 20 and 40 mg groups 
maintained a nearly normal body composition [30,32]. Con- 
trasting with the above data, is a recent report [24] that ad- 
ministration of up to 45 mg acarbose/100 g in a high sucrose 
diet to female Sprague-Dawley rats for 20 days resulted in a 
significant reduction in food intake and body weight. Meal 
sizes were reported to be decreased but meal frequency was 
increased at the highest dose of acarbose. 
It should also be noted that in one study [I 1], acarbose 
added in a range of doses (including 80 mg/100 g diet) to a 
starch diet comparable to the one used here actually resulted 
in significant dose-dependent increases in daily food intake 
in female Sprague-Dawley rats over a period of 14 days. 
However, body weights were markedly reduced under this 
drug regimen. Mixed in a high-fat diet, acarbose had no sig- 
nificant effects overall, but resulted in a general trend for 
suppression of food intake, which was significant only at 
the large dose of 80 mg/100 g diet. No significant effects on 
the rats' body weight were obtained following 14-days of a 
high-fat diet [11]. 
The effectiveness of acarbose as an anti-obesity agent 
thus appears to vary with the nature of the diet, duration of 
drug administration, and the type of obesity studied [11, 17, 
24, 30-32]. Acarbose appears most effective in preventing 
body weight gain in young, growing rats fed a sucrose- 
supplemented diet, although as discussed above, the re- 
ported food intake data are not always in complete agree- 
ment. Acarbose proved ineffective when mixed with a high- 
fat diet, and actually resulted in increased food intake when 
mixed into a high starch diet [I1]. Using powdered labora- 
tory chow (high starch) and a high dose of acarbose, we 
failed to modify the rats' food intakes or influence the pa- 
rameters of meal-taking behavior. 
It is also possible that the effects of acarbose on food 
intake may be influenced by the rats' age or the duration of 
treatment. Zucker rats used in the present study were 13 
weeks old with mean body weights of 462 g for the obese and 
317 g for the lean group. In the study by Vasselli et al. [31] 
male Zucker rats weighed less than 200 g at 7 weeks of age 
and presumably showed a more rapid rate of growth. In that 
study [31] food intake of obese rats (age 7 weeks) was signifi- 
cantly reduced following the high dose of acarbose (40 
mg/100 g diet) during the first week of acarbose treatment but 
at no time thereafter. Furthermore, obese rats fed the 
medium dose of acarbose (20 mg/100 g diet) showed a 
gradual tendency towards an increased daily intake [31]. As 
noted previously, acarbose-fed obese rats maintained their 
obese body composition on a percentage basis at levels not 
significantly different from that of the 0 mg obese control 
group. The only other study [18] to report the effects of 
acarbose on food intakes of obese Zucker rats used mature 
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male Zucker rats (weight range 558-585 g) over a 28-day 
period. These rats were reported to lose between 30--100 g of 
body weight when fed both 40 and 80 rag/100 g acarbose and 
to reduce their food consumption by up to 34%, although it is 
not clear how the percentage reduction in food intake was 
calculated. These two reports are clearly at odds, and our 
data on the short-term effects of  two inhibitors of carbo- 
hydrate absorption appear to be more consistent with those 
of  Vasselli et al. [31] in demonstrating that the food intakes 
of  obese rats were unaffected by acarbose. 
While acarbose may prevent the development of dietary 
obesity in young rapidly growing rats, there is little informa- 
tion on the effects of acarbose on body composition of ma- 
ture and already obese Zucker rats. Given the demonstrated 
ability of the Zucker rat to divert ingested energy towards fat 
deposition even in the face of caloric restriction [16], it is 
possible that acarbose would not be effective in altering body 
composition of mature, obese Zucker rats. The clinical use- 
fulness of commercial inhibitors of  carbohydrate absorption 
in the management of human obesity remains doubtful [3], 
especially given the undesirable side effects produced by 
carbohydrate malabsorption [1]. More recently, it has been 
suggested that inhibitors of carbohydrate absorption might 
be more useful in the treatment of  diabetes than as 
antiobesity agents [12,22]. Several non-oligosaccharide in- 
hibitors of  carbohydrate absorption which appear to avoid 
the malabsorption problems of  acarbose and similar com- 
pounds have recently been described and are in early clinical 
trials [20]. 
Previous research on antiobesity drugs has primarily fo- 
cused on modulation of carbohydrate rather than lipid me- 
tabolism. However ,  animal studies on hyperphagia and di- 
etary obesity indicate that some of the most effective obesity 
promoting diets are high in fat as well as sugar. These include 
"supermarket"  diets (chocolate chip cookies, salami) or 
powdered chow supplemented with Crisco or with 
sweetened condensed milk [9,23]. The more recently devel- 
oped inhibitors of lipid absorption or synthesis may be better 
suited to deal with excessive ingestion of dietary fats. Previ- 
ous studies on Ro 22-0654 and Ro-0083 have addressed 
primarily their effects on metabolism and body composition. 
Chronic administration of  Ro 22-0654 produced a marked 
weight loss in both obese and lean Zucker rats [29]. Prelimi- 
nary reports suggest that inhibition of fatty acid synthesis 
produced by this compound was not the result of changes in 
the activities of acetyl CoA carboxylase, fatty acid synth- 
etase, or citrate cleavage enzyme (Triscari and Sullivan, un- 
published observations. Body composition studies indicate 
that the weight loss in obese and lean Zucker rats following 
chronic treatment with Ro 22-0654 was attributable primarily 
to a significant decrease in carcass lipid content, although an 
initial transitory decrease in food intake was observed as 
well [29]. The present data indicate that inhibitors of periph- 
eral lipid metabolism have significant acute effects on the 
daily food intakes of laboratory rats, which is consistent with 
their reported effects on body composition. 
The present findings that inhibitors of lipid metabolism 
reduced food intake during three days of  treatment suggest a 
link between lipid metabolism and the regulation of food 
intake that may be exploited further in the pharmacological 
management of obesity. The inhibitors of lipid synthesis (Ro 
22-0654) and of pancreactic lipase (Ro 20-0083) reduced food 
intakes of both obese and lean rats primarily through their 
action on meal size. The observed reduction in meal fre- 
quency suggests further that these agents may delay meal 
initiation and may promote earlier satiation during a meal. 
While compensatory hyperphagia during recovery was ob- 
served in lean rats, no rebound feeding was observed in the 
obese. It should be noted here that the reported effects are 
for acute drug treatment only, and that preliminary long term 
studies of food intake suggest that some of the anorectic 
effects of  peripherally acting compounds may be abolished 
following several consecutive days of drug administration 
[29]. Nevertheless the potential short-term anorexia in com- 
bination with the long term effects of these agents on lipid 
metabolism may provide a basis for new treatment modal- 
ities in obesity management. 
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